Default company panoramic image
8cd626bc 36a6 40b3 a5e9 61ce5572f6c8

LytPhage, Inc.

LytPhage is developing novel and prorietary therapeutics to treat the increasing worldwide crisis of antibiotic resistant infections.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Malvern, PA, US
  • Currency USD
  • Founded January 2015
  • Employees 1
  • Website lytphagepharma.com

Company Summary

LytPhage and its collaborators at Temple University are developing novel antibiotic products that harness modified bacterial viruses (phage). They are an attractive alternative to synthetic and fermentation derived antimicrobials because phage can infect and kill only bacterial cells (and not mammalian cells). The technology can be applied to a long list urgent clinical problem like resistant staph, pseudomonas, C. difficile, and others.

Advisors

  • Default avatar
    Roy Stevens, DDS, MS
    Chief Scientific Advisor
    Unconfirmed
    Default avatar
    Kenneth Kovan
    Business and Marketing Advisor
    Unconfirmed
    Default avatar
    Ted Kirsch, PhD
    Clinical and Regulatory Advisor
    Unconfirmed